As the CEO of Psycheceutical Bioscience, Inc., I’m on a mission to advance next-generation technologies to provide the safe and effective delivery of psychedelic pharmaceutical medicines that can be used across the mental health treatment spectrum.
I’ve been at the forefront of promoting alternative medicines such as psychedelics and cannabis to help treat diseases where traditional pharmaceuticals have failed. As research advances, we’re realizing that these medicines can have a significant impact to not only revolutionize healthcare treatment, but also to kick off a one-in-a-generation industry with huge potential returns for investors. By specifically designing these delivery technologies to be administered through telehealth or at home, we can greatly lower the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
As a 25-year cannabis, healthcare, and biotech executive, I possess truly unique leadership across operations, technology, manufacturing, finance, and product/drug development. I’m a highly ambitious and results-centric leader focused on developing corporate growth and execution strategies to maximize efficiency and profitability. Previously, I held the CEO position of True Lab, am a current partner at Artis Intel, and a board member of Ainnova Tech.
Additionally, I have been publicly recognized for my work, cited in high-level outlets such as Forbes and Benzinga as well as cannabis-specific publications such as High Times. I’ve also been featured on numerous podcasts to share my experience and thoughts on the mental health crisis and the potential of psychedelics as a solution.